95 completed, 8 unknown, 4 terminated, 3 recruiting. 47 Phase 4, 26 Phase 3, 21 Phase 2, 8 Phase 1, 6 Not applicable.
Follow Bimatoprost: new trials by email Literature Review of Bimatoprost trials Research Report on Bimatoprost
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension Bimatoprost ophthalmic solution 0.01% YSBP, bimatoprost ophthalmic solution 0.01% (Lumigan®) - Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH) | Phase 3 | Recruiting | YS Life Science Co., Ltd. | 600 | 2026-06-02 | 2026-09-23 |
| Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy Prostaglandin Analogue -Containing IOP-Lowering Therapy, Beta Blocker, Brillouin Microscopy - Glaucoma | Recruiting | University of Maryland, Baltimore | 60 | 2025-09-01 | 2026-08-10 | |
| A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01% - Open-angle Glaucoma, Ocular Hypertension | Phase 1 | Unknown | Amneal Pharmaceuticals, LLC | 240 | 2024-04-01 | 2024-08-06 |
| Treatment of Hypopigmented Scars With Bimatoprost Bimatoprost, Saline - Scars, Hypopigmented Scar | Phase 2 | Unknown | Medstar Health Research Institute | 25 | 2023-07-18 | 2024-05-03 |
| Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes. Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) - Glaucoma, Open-Angle, Ocular Hypertension | Phase 3 | Recruiting | Amneal Pharmaceuticals, LLC | 168 | 2022-06-29 | 2022-08-10 |
| Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment Bimatoprost, Excimer laser, Microneedling with a dermaroller - Vitiligo | Early Phase 1 | Completed | Medical University of South Carolina | 4 | 2021-11-02 | 2022-08-05 |
| Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) - Glaucoma, Open-Angle | Phase 3 | Completed | Mankind Pharma Limited | 310 | 2021-10-02 | 2022-12-13 |
| Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting Tafluprost, timolol maleate - Ocular Surface Disease, Primary Open Angle Glaucoma | Completed | Santen Pharmaceutical (Taiwan) Co., LTD | 50 | 2021-09-01 | 2022-10-31 | |
| Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma Netarsudil Ophthalmic, Bimatoprost Ophthalmic - Normal Tension Glaucoma | Phase 4 | Unknown | Salus University | 115 | 2021-08-01 | 2021-08-06 |
| Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma Triple combination formula, Bimatoprost .03% sterile ophthalmic solution - Glaucoma, Quality of Life (QOL) | Phase 4 | Active not recruiting | Federal University of São Paulo | 40 | 2021-03-01 | 2025-01-07 |
| AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension AGN-193408 SR, Lumigan, Sham Administration - Open-angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Active not recruiting | AbbVie | 100 | 2020-11-16 | 2026-05-22 |
| A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension Bimatoprost SR, LUMIGAN - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | AbbVie | 37 | 2020-06-11 | 2023-06-08 |
| A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension SDP-133, Lumigan - Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Withdrawn | Sun Pharmaceutical Industries Limited | 2019-06-10 | 2021-11-19 | |
| Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension Bimatoprost (SR) - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | AbbVie | 515 | 2019-02-28 | 2025-08-19 |
| Combined CO2 Fractional Laser With Bimatoprost 0.03% Treatment of Alopecia Areata Bimatoprost 0.03% solution, CO2 fractional laser - Alopecia Areata | Phase 1 / Phase 2 | Completed | Ahmed Hassan Nouh MD | 30 | 2019-01-01 | 2022-10-31 |
| Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients Bimatoprost, Lumigan® - Ocular Hypertension, Glaucoma | Phase 3 | Completed | Laboratoires Thea | 485 | 2018-11-23 | 2023-11-21 |
| Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo Bimatoprost 0.03% ophthalmic solution - Generalized Vitiligo | Phase 4 | Unknown | Assiut University | 40 | 2018-05-01 | 2018-04-03 |
| Topical Bimatoprost in the Treatment of Migraine Bimatoprost Topical Solution, Control - Migraine Disorders, Headache Disorders | Phase 2 | Unknown | Manistee Partners | 70 | 2018-01-05 | 2019-04-26 |
| Topical Bimatoprost for Chemical Blepharoplasty bimatoprost 0.03% ophthalmic solution - Dermatochalasis | Early Phase 1 | Completed | Tulane University | 15 | 2016-11-01 | 2021-03-05 |
| Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia Bimatoprost 1% Formulation A, Bimatoprost 1% Formulation B - Androgenetic Alopecia | Phase 1 | Completed | Allergan | 11 | 2016-07-01 | 2016-10-26 |
Showing 20 of 115. Sign in to see all of them.
Ocular Hypertension (63) · Glaucoma (42) · Glaucoma, Open-Angle (40) · Hypotrichosis (6) · Alopecia (4) · Alopecia Areata (3) · Graves Ophthalmopathy (3) · Vitiligo (3) · Graves Disease (2) · Cicatrix (1) · Cicatrix, Hypertrophic (1) · Corneal Diseases (1) · Cutis Laxa (1) · Glaucoma, Angle-Closure (1) · Headache (1)
Allergan (54) · Alcon Research (5) · ForSight Vision5, Inc. (5) · Innovative Medical (4) · AbbVie (3) · Amneal Pharmaceuticals, LLC (2) · Aristotle University Of Thessaloniki (2) · Duke University (2) · Laboratoires Thea (2) · University of Miami (2) · ATS Clinical Research (1) · Afyon Kocatepe University Hospital (1) · Ahmed Hassan Nouh MD (1) · Assiut University (1) · Cardiff University (1)
United States (67) · Canada (8) · United Kingdom (8) · Germany (7) · Brazil (5) · Italy (5) · Greece (4) · Israel (4) · Japan (4) · Spain (4) · Australia (3) · Austria (3) · Belgium (3) · China (3) · Czechia (3)
Michelle Chen, PhD (5) · Robert Noecker, MD (4) · Alan L. Robin, MD (1) · Alana M Santana, MD (1) · Amandeep S Rai, MD (1) · Anastasios G Konstas, MD, PhD (1) · Anastasios Konstas, MD, PhD (1) · Andrea L. Kossler, M.D. (1) · Anne McLaughlin (1) · Ava Shamban, MD (1) · Carolina Gracitelli, Affiliate Professsor (1) · Christophe Baudouin, Professor (1)
PMID 19855289, PMID 15577756, PMID 17459480, PMID 17686450, PMID 19620039, PMID 19825835, PMID 20115946, PMID 20346780, PMID 20384750, PMID 20384751, PMID 21199096, PMID 21712909, PMID 21899919, PMID 22918671, PMID 23475405, PMID 23873891, PMID 24006861, PMID 24643895, PMID 24667994, PMID 25432143, PMID 25601618, PMID 25613811, PMID 25765294, PMID 26060513, PMID 28528010, PMID 29057117, PMID 31245963, PMID 31321800, PMID 32089329, PMID 32478930, PMID 35076329, PMID 35643967, PMID 36370233, PMID 37343625, PMID 39985740
2009 (1), 2015 (1), 2018 (1), R01EY014957 (1), R21EY035483 (1)